Antiy Sunshine
Suzhou
About Antiy Sunshine
Antiy Sunshine develops antisense oligonucleotide (ASO) drugs targeting RNA splicing and RNA editing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $16.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2024)
- Website: aso-cura.com
Industries & Categories
Medical, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/antiy-sunshine-67936 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.